Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and an extensive network of long-standing trusted partners enabling a commercial presence in more than 90 countries.
Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision.
Via Pian Scairolo 9 6912 Pazzallo/Lugano |
T.: +41 91 985 21 21 |
F.: +41 91 993 21 22 |
http://www.helsinn.com |
info-HHC@helsinn.com |
https://www.linkedin.com/company/101863/ |
-
Attività principali Licensing-In ● Licensing-Out ● -
Fasi di sviluppo Pre-clinical ● Phase I - Phase III ● Registration ● Market ● Life cycle management ● -
Aree terapeutiche Cancer supportive therapy ●